What is Thoracent?
Thoracent specializes in the development and distribution of pulmonary and thoracic medical products within the U.S. market. Their product portfolio is anchored by the BONASTENT tracheobronchial stent, a testament to their focus on innovative solutions for respiratory and esophageal conditions. The company also offers advanced tracheobronchial and esophageal stents, distinguished by their unique nitinol woven structure and an ultra-slim delivery system. Further broadening their reach, Thoracent serves as the exclusive U.S. distributor for the Y-Stent, a product manufactured by Micro-Tech Endoscopy. The company's consistent growth has been recognized through multiple appearances on the Inc5000 list of fastest-growing private companies, highlighting a strong trajectory in a specialized medical niche.
How much funding has Thoracent raised?
Thoracent has raised a total of $138K across 1 funding round:
Debt
$138K
Debt (2021): $138K with participation from PPP
Key Investors in Thoracent
PPP
Public-Private Partnership
What's next for Thoracent?
With a substantial large-scale late-stage funding context, Thoracent is strategically positioned for accelerated expansion and market penetration. The recent strategic investment likely signals confidence from backers in the company's established product lines and its potential for further innovation and market share growth. Future endeavors may include scaling manufacturing capabilities, expanding the sales and distribution network, and potentially investing in research and development for next-generation thoracic and pulmonary devices. This capital infusion is expected to fuel Thoracent's continued ascent as a key player in the U.S. medical device market, particularly in the specialized field of stenting solutions.
See full Thoracent company page
